Israel's Pluristem sees positive results from leg pain study
TEL AVIV (Reuters) - Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC). (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Cardiovascular Systems touts 18-month Liberty PAD study data
Cardiovascular Systems (NSDQ:CSII) today released 18-month results from the Liberty 360° study of peripheral artery disease interventions, touting high freedom from adverse events and amputations.
Results from the study were presented by Dr. William Gray of Wynnewood, Penn.’s Lankenau Heart Institute at the Cardiovascular Research Technologies 2018 interventional cardiology conference in Washington D.C., the St. Paul, Minn.-based company said.
“The 18-month Liberty 360° results continue to show that PVI, including the use of orbital atherectomy, can lead to amputation free survival for patients with claudica...
Source: Mass Device - March 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular Cardiovascular Systems Inc. Source Type: news
PQ Bypass wins IDE nod for Detour percutaneous femoropopliteal bypass study
PQ Bypass said today it won FDA investigational device exemption approval to launch a pivotal clinical trial of its Detour percutaneous femoropopliteal bypass system designed to treat patients with peripheral artery disease.
The company’s Detour II clinical trial will look to enroll up to 292 patients with lower limb ischemia due to long blockages over 15 cm in the superficial femoral artery, the Sunnyvale, Calif.-based company said.
“We worked closely with the FDA, leading physicians and healthcare administrators to design a trial that we expect to demonstrate the total value of this unique approach to treati...
Source: Mass Device - December 13, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Regulatory/Compliance Stent Grafts Vascular PQ Bypass Source Type: news
Wearable Activity Monitor May Improve Intermittent Claudication Outcomes Wearable Activity Monitor May Improve Intermittent Claudication Outcomes
Supplementing supervised exercise programs with the use of a wearable activity monitor may boost walking distances and quality of life in patients with intermittent claudication, according to a pilot study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2017 Category: Consumer Health News Tags: News Source Type: news
Quality of care for peripheral artery disease is low
This study is a “call to action” to identify and implement effective physician-targeted and patient-targeted strategies aimed at improving quality of care. These strategies should take advantage of recent advances in behavior change, including leveraging an individual’s social support network to help them mak e lifestyle changes, and providing physicians with feedback about the quality of care they provide to patients with peripheral artery disease.AUTHORSJoseph Ladapo of UCLA and Jeffrey Berger of New York University.JOURNALThe studyis published online by the Journal of the American College of Cardiology.FUNDINGThe...
Source: UCLA Newsroom: Health Sciences - May 1, 2017 Category: Universities & Medical Training Source Type: news
Shockwave Medical launches lithoplasty trial
Shockwave Medical said today it enrolled the 1st patient in the Disrupt PAD III trial of its Lithoplasty system, aiming to explore the system’s effectiveness at treating heavily calcified lesions in the leg compared to traditional angioplasty.
The company’s Lithoplasty device is designed to use intermittent lithotripsy pulses to disrupt superficial and deep vascular calcium and an angioplasty balloon to expand blockages at low pressures to restore blood flow.
The 334-patient trial will have a primary goal of achieving less than 30% residual stenosis without the need for stenting, and all patients who do no...
Source: Mass Device - April 5, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Vascular Shockwave Medical Source Type: news
Claudication: Endovascular Therapy-Exercise Combo Best Bet
(MedPage Today) -- Meta-analysis supports insurance coverage of exercise programs (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 3, 2017 Category: Cardiology Source Type: news
Pseudoclaudication: Is it related to claudication?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - March 7, 2017 Category: Consumer Health News Source Type: news
Vertos Medical wins CMS reimbursement for Mild procedure
Vertos Medical said today it won national coverage for its Mild procedure designed to treat lumbar spinal stenosis from the Centers for Medicare & Medicaid Services.
The Mild procedure won coverage through a recently approved study as part of CMS’ Coverage with Evidence Development Program, the Aliso Viejo, Calif.-cased company said.
Access to the procedure was granted via a CMS-approved claims-analysis study which will passively collect and analyze real-world data on the procedure.
“Patient and physician demand for the Mild procedure has grown a great deal, and I’m excited to hear that my patients a...
Source: Mass Device - March 7, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Spinal Vertos Medical Source Type: news
Pluristem closes enrolment for Phase II trial of PLX-PAD cells to treat intermittent claudication
Israeli-based drug development company Pluristem Therapeutics has closed enrolment for its Phase II trial of placental expanded (PLX-PAD) cells to treat intermittent claudication (IC), a peripheral artery disease (PAD). (Source: Drug Development Technology)
Source: Drug Development Technology - January 16, 2017 Category: Pharmaceuticals Source Type: news
MassDevice.com +5 | The top 5 medtech stories for September 23, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Medtronic escapes Infuse lawsuits involving fugitive Ohio doc
Medtronic yesterday escaped hundreds of lawsuits filed over the allegedly off-label use of its controversial bone-growth product, Infuse, by a Cincinnati doctor who ...
Source: Mass Device - September 23, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Medtronic touts low CD-TLR rates, strong durability in 3-year In.Pact Admiral DCB study | VIVA 2016 Roundup
Medtronic (NYSE:MDT) this week released data from 2 clinical studies evaluating its In.Pact Admiral drug-coated balloon for treating claudication and restenosis, touting sustained durability at 3-years.
Results were presented at the Vascular Interventional Advances 2016 conference in Las Vegas this week.
3-year outcomes from the In.Pact SFA trial showed Medtronic’s balloon had long-term clinical benefit superior to plain balloon angioplasty, reported Dr. Prakash Krishnan of New York’s Mt. Sinai Heart.
“The In.Pact Admiral is the only DCB to-date with superior performance supported by three-year data,&#...
Source: Mass Device - September 22, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Endoscopic / Arthroscopic C.R. Bard Medtronic Mercator MedSystems Shockwave Medical Source Type: news
Revascularization May Best Medical Therapy for Leg Claudication Revascularization May Best Medical Therapy for Leg Claudication
Patients treated for intermittent leg claudication with revascularization report significantly better outcomes than those receiving medical therapy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2016 Category: Consumer Health News Tags: Internal Medicine News Source Type: news
Study: Revascularization beats medical management for intermittent claudication in PAD
Revascularization through endovascular or surgical interventions may be superior to medical management for peripheral artery disease patients with intermittent claudication, according to a new study from the University of Washington, Seattle.
Data from the study was published online in JAMA Surgery.
The study reported that patients with intermittent claudication, which presents as pain in the calf or foot while walking, who underwent revascularization procedures showed improved walk function, reported better health-related quality of life and fewer symptoms of claudification at 12 months than those who were treated only ...
Source: Mass Device - August 17, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Surgical Vascular JAMA Surgery Journal of the American Medical Assn. (JAMA) Source Type: news
Revascularization Associated with Better Function in Intermittent Leg Claudication (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
In patients with intermittent leg claudication, revascularization may lead to greater gains in function, symptoms, and quality of life than medical therapy. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 17, 2016 Category: Primary Care Source Type: news
